Background: Metabotropic glutamate receptor subtype 5 (mGlu 5 ) activators have emerged as a novel approach to the treatment of schizophrenia. Positive allosteric modulators (PAMs) of mGlu 5 have generated tremendous excitement and fueled major drug discovery efforts. Although mGlu 5 PAMs have robust efficacy in preclinical models of schizophrenia, preliminary reports suggest that these compounds may induce seizure activity. Prototypical mGlu 5 PAMs do not activate mGlu 5 directly but selectively potentiate activation of mGlu 5 by glutamate. This mechanism may be critical to maintaining normal activity-dependence of mGlu 5 activation and achieving optimal in vivo effects.
A large number of clinical and preclinical studies increasingly support the hypothesis that selective activators of a metabotropic glutamate receptor subtype 5 (mGlu 5 ) may provide a novel therapeutic approach for treatment of schizophrenia, cognitive disorders, and some genetic childhood developmental disorders. A major breakthrough that allowed mGlu 5 selective activators to emerge as a viable approach was discovery of highly selective positive allosteric modulators (PAMs) of this receptor. Discovery of selective allosteric modulators is providing fundamental advances in our understanding of G protein-coupled receptor (GPCR) signaling and modulation, causing a paradigm shift in studies of GPCR signaling and drug discovery (1) . Unlike traditional agonists, GPCR PAMs do not activate the receptor directly but maintain dependence on normal signaling mechanisms, selectively increasing receptor responses to endogenous agonists. Theoretically, this unique property of PAMs could provide therapeutic advantages by maintaining the normal temporal and spatial requirements of receptor activation by natural agonists. However, at present, there has been no clear demonstration that PAMs of mGlu 5 or other GPCRs can elicit fundamentally different effects from traditional agonists in intact systems.
One of the most exciting aspects of targeting mGlu 5 for treatment of schizophrenia is that mGlu 5 PAMs have potential utility in treatment of all major symptom domains (positive, negative, and cognitive symptoms) (1) (2) (3) (4) . Animal studies reveal that mGlu 5 PAMs have robust efficacy in rodent models predictive of antipsychotic efficacy and enhance multiple aspects of cognitive function (5) (6) (7) (8) (9) (10) . However, recent preliminary reports suggest that mGlu 5 PAMs may also have severe targetdependent adverse effects, including induction of behavioral convulsions (11) (12) (13) (14) , potentially preventing mGlu 5 PAMs from advancing to clinical development. Interestingly, traditional mGlu 5 agonists can also induce seizure activity (15, 16) . This is especially important in light of recent studies suggesting that some mGlu 5 PAMs exhibit allosteric agonist activity when evaluated in overexpressing cell lines (11, 17) ; however, this has only been observed with artificially high levels of mGlu 5 expression (9) . It is not known whether mGlu 5 PAMs that have been evaluated in vivo elicit functionally relevant agonist activity and the potential impact of allosteric agonist activity in the central nervous system (CNS) has not been evaluated.
Given the recent findings of adverse effects of mGlu 5 PAMs and the potential impact of authentic allosteric agonist activity in mGlu 5 PAMs if it exists, we engineered an inducible cell line allowing assessment of novel mGlu 5 PAMs for allosteric agonist activity with either high or low levels of mGlu 5 expression. Interestingly, we found that closely related mGlu 5 PAMs can exhibit fundamentally different profiles in terms of mGlu 5 allosteric agonist activity. Most notably, the mGlu 5 PAM VU0424465 has robust allosteric agonist activity in a lowexpressing cell-based system and in multiple native systems. Moreover, VU0424465 induces intense epileptiform activity in hippocampal slices and generalized seizure activity and behavioral convulsions in rats. In contrast, closely related compounds behave as pure mGlu 5 PAMs with no observable agonist activity in any cell line or native system. These compounds exhibit in vivo efficacy in animal models predictive of antipsychotic activity but do not induce seizure activity or observable adverse effects. Thus, subtle structural changes can lead to a molecular switch of pure mGlu 5 PAMs to robust mGlu 5 allosteric agonists, dramatically altering the effects of mGlu 5 PAMs CNS. This provides direct demonstration that maintaining activity-dependence of mGlu 5 activation with pure mGlu 5 PAMs can provide major advantages, avoiding adverse effect liabilities observed with mGlu 5 agonists. These critical new mechanistic insights reveal key advantages of mGlu 5 PAMs and the critical importance of chemically optimizing pure PAMs using native systems and cell lines that do not overexpress mGlu 5 to achieve efficacy without inducing adverse effects associated with direct receptor activation.
Methods and Materials

Materials
Dulbecco's Modified Eagle's Medium, fetal bovine serum, and antibiotics were purchased from Invitrogen (Carlsbad, California). Dihydroxyphenylglycine (DHPG) and LY341495 were purchased from Ascent Scientific (Bristol, United Kingdom) and Tocris (Ellisville, Missouri), respectively. VU0422465 (18), VU0361747 (10), 5-methyl-6-(phenylethynyl)-pyridine (5MPEP) (19) , and 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine (MTEP) (20) were synthesized as described previously. Unless otherwise stated, all other reagents were purchased from Sigma-Aldrich (St. Louis, Missouri) and were either analytical or high-performance liquid chromatography grade.
Cell Culture and Mutagenesis
HEK293A cells lines stably expressing rat mGlu 5 were maintained (9) , and point mutations were introduced into rat mGlu 5 and polyclonal stable cell lines generated (21), as described previously.
Fluorescence-Based Calcium Assays in Rat mGlu 5 Cells
Measurement of mGlu 5 -mediated intracellular Ca 2ϩ mobilization was performed using the Ca 2ϩ sensitive dye, Fluo-4, and a Flexstation II, as described previously (9) . Data were transformed and fitted using GraphPad Prism 5.0 (Graph-Pad Software, San Diego, California).
Brain Slice Electrophysiology
Animals were cared for in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Rats were 5 to 6 weeks for long-term depression (LTD) and 24 to 30 days for epileptiform activity. LTD experiments were conducted as previously described (9) . For epileptiform experiments, 400-mm transverse slices were made as described for LTD experiments, except that slices were transferred directly from cutting to room temperature artificial cerebrospinal fluid (ACSF; in mmol/L: 124 NaCl, 5 KCl, 1.25 NaH 2 PO 4 , 26 NaHCO 3 , 10 glucose, 2 CaCl 2 , 1.2 MgCl 2 ) for 1 hour. Slices were transferred to the recording chamber and perfused with 301C to 321C ACSF. Recording electrodes were placed in the cell body layer of CA3. Field potential recordings (spontaneous events) were acquired. mGlu 5 compounds or DHPG were applied using a perfusion system. Sampled data was analyzed offline using MiniAnalysis (Synaptosoft, Fort Lee, New Jersey) to determine the amplitude and interevent interval of the spontaneous events and normalized to the predrug period. 20 and EC 80 of glutamate following the addition of vehicle alone. Static ratio represents relative fluorescence units normalized to initial values. VU0424465, but not VU0361747, clearly induces a concentration-dependent release of calcium when added alone. Potencies were determined by adding a concentration-response curve of VU0424465 (B) followed by an EC 20 of glutamate (PAM) or (C) in the absence of glutamate (agonist). VU0424465 potentiated the calcium mobilization evoked by glutamate in a concentration-dependence manner. The PAM EC 50 of VU0424465 is 1.5 nmol/L, whereas the agonist potency is 171 nmol/L with a 65% maximum glutamate response. Data represent the mean Ϯ SEM of five independent experiments performed in duplicate. For these studies, rat mGlu 5 -expressing cell lines were used for full in vitro characterization of novel compounds to correlate in vitro data to in vivo studies in rats; similar potency/efficacy profiles were observed in human mGlu 5 -expressing cell lines.
In Vivo Electroencephalography (EEG)
EEG recordings and analysis were performed as described previously (22) . Male Sprague-Dawley (225-250 g) rats were implanted with a single cortical EEG electrode and allowed to recover for 7 days. Animals were placed in an open field chamber where continuous video and EEG data were collected for 24 hours. The EEG signals were amplified (5000 Â gain; high-pass filter 1 Hz; low-pass filter 100 Hz), digitized at 500 Hz, and acquired with AcqKnowledge software (Biopac Systems, Santa Barbara, California). Compounds were diluted in 10% Tween 80 (pH 7.0) at a concentration of 1 mg/3 mL, and injected intraperitoneally. The number of spikes from each EEG trace was counted with a threshold of 3 SD from the mean baseline taken before the injection of the compound. Both positive and negative events were counted, and the mean and 95% confidence intervals (CI) were calculated for each group.
Behavioral Manifestations of Seizure Activity
Rats received treatment of 56.6 mg/kg VU0361747, 10 mg/kg VU0422465, or 10 mg/kg VU0422465 ϩ 3 or 10 mg/kg MTEP. Compounds were formulated in 10% Tween 80 (pH 7.0) at a concentration of 1 mg/3 mL and injected intraperitoneally. Animals were monitored continuously and scored for behavioral manifestations of seizure activity in 5-min periods, once every 5 min for the first 15 min, then once every 15 min up to 1 hour, and every 30 min up to 2 hours. Behavioral manifestations of seizures were scored using a modified Racine scoring system (23) . Briefly, a score of 0 represents no behavior alterations; score 1, immobility, mouth and facial movements, or facial clonus; score 2, head nodding, tail extension; score 3, forelimb clonus, repetitive movements; score 4, rearing and tonic clonic seizure; and score 5, continuous rearing and falling, severe generalized tonic clonic seizure. Rats were then euthanized agonist concentration-response curve with no effect on the maximum response, suggesting a competitive interaction of VU0424465 with the allosteric mGlu 5 MPEP site. (B) Multiple single point mutations that eliminate calcium mobilization by the orthosteric agonists, glutamate and dihydroxyphenylglycine (DHPG), did not abolish VU0424465-induced agonist activity. (C) Introduction of the single point mutation A809V, which abolishes activity at the mGlu 5 allosteric MPEP-site, eliminated agonist activity evoked by VU0424465. This mutation had no effect on orthosteric agonist activity of glutamate or DHPG (data not shown). The single point mutation, F585I, known to inhibit activity of the allosteric positive allosteric modulator CPPHA, had no effect on VU0424465 agonist activity. Data represent the mean Ϯ SEM of three independent experiments performed in duplicate.
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Statistical Analysis
Data are reported as mean Ϯ SEM. Analysis of LTD experiments was performed using a one-way analyses of variance (ANOVA) with Tukey post hoc test. Statistical analysis of epileptiform electrophysiological experiments was performed using a one-way ANOVA with a Dunnett's post hoc test. For effect of drug treatment and time on behavioral convulsions, a two-way, repeated-measures ANOVA was used. Differences between treatment groups and within treatment groups over time were identified using Tukey post hoc tests. Comparison of spike rate (mean ϩ 95% CI) from cortical EEG recordings between vehicle and VU0424465-or VU0361747-treated groups was performed using a Student t test. For all test, statistical significance was considered p Ͻ .05.
Results
Optimization of mGlu 5 PAMs with Allosteric Agonist Activity
We previously reported discovery of a novel mGlu 5 PAM series, finding that some compounds behaved as pure PAMs, whereas others exhibited allosteric agonist activity (9, 10) . Interestingly, this allosteric agonist activity was only observed in cell lines expressing high levels of mGlu 5 and not in lower-expressing cell lines or in native systems, suggesting that agonist activity can be an artifact of overexpression of the receptor and not indicative of physiologic effects or in vivo efficacy (9) . We sought to develop VU0360172-based mGlu 5 PAMs that possessed allosteric agonist activity in low mGlu 5-expressing cell lines. Chemical optimization efforts led to VU0424465, the most potent and efficacious compound within this scaffold ( Figure S1 in Supplement 1). Novel compounds derived from this scaffold were evaluated for agonist activity in previously described rat HEK293 cells expressing low levels of mGlu 5 (9) similar to those seen in native tissues and most representative of physiologic systems. Consistent with our previous report (9), these mGlu 5 PAMs did not display agonist activity in inducing calcium mobilization in cells expressing low levels of mGlu 5 but did potentiate the response to an EC 20 concentration of glutamate, as demonstrated by VU0361747 ( Figure 1A ), a compound behaving as a pure PAM regardless of mGlu 5 expression levels (9) . Interestingly, the newly discovered compound, VU0424465, exhibited robust agonist activity and induced calcium mobilization in the absence of glutamate (EC 50 ¼ 171 Ϯ 15 nmol/L, maximum efficacy 65% compared to glutamate; Figure 1C ). Historical PAMs, such as CDPPB, have been reported to possess minimal agonist activity in various cell-based assays. In the mGlu 5 low-expressing cell line, the maximum agonist effect observed was 13% of the glutamate response with an EC 50 of 5.8 mmol/L (data not shown). Although previously reported PAMs, such as CDPPB, provided the first tool compounds to assess in vivo efficacy in behavioral models (6, 7, 24, 25) , the magnitude of agonist activity coupled with its poor solubility and brain penetration made it necessary to optimize new compounds that possessed ideal physicochemical and pharmacokinetic properties to achieve adequate unbound brain concentrations to assess the effects of allosteric agonist activity in vivo. VU0424465 potentiated glutamate-induced calcium mobilization, displaying a potency of 1.5 Ϯ .8 nmol/L ( Figure 1B ) and induced a 6.6-fold shift in the glutamate concentration-response curve (data not shown). Additional studies assessing the ability of 10 mmol/L VU0424465 to modulate glutamate activity at other mGlu subtypes, demonstrated that this compound is highly selective for mGlu 5 ( Figure S2A in Supplement 1).
Agonist Activity of VU0424465 Mediated by Interaction with an Allosteric Site
To assess whether VU0424465 interacts with the previously identified allosteric binding site, we evaluated its ability to inhibit binding of [ 3 H]methoxy-PEPy to the MPEP allosteric binding site on mGlu 5 . VU0424465 exhibited high affinity at this site with a K i value of 11.8 Ϯ .1 nmol/L ( Figure S2B in Supplement 1) . Additionally, pharmacologic studies revealed that the mGlu orthosteric antagonist LY341495 (100 mmol/L-1 mmol/L) did not shift VU0424465 agonist activation of mGlu 5 (Figure 2A ). VU0424465 also did not inhibit binding of the group I orthosteric binding site radioligand [
3 H]quisqualate to rat mGlu 5 -expressing cell membranes (data not shown). These results suggest that VU0424465 does not act as a traditional orthosteric site agonist. In contrast, the neutral allosteric MPEP-site ligand, 5MPEP (30 mmol/L-300 mmol/L), induced concentrationdependent parallel rightward shifts of the VU0424465 agonist concentration-response curve with no effect on the maximum response ( Figure 2A ). These data suggest that VU0424465-induced activation of mGlu 5 is mediated by a competitive interaction with the MPEP allosteric binding site.
To confirm further that VU0424465 behaves as an allosteric agonist, individual single point mutations, substituting amino acids known to be essential for orthosteric ligand binding (R68E and D304A) and activation at mGlu 5 (C240E) were introduced into rat mGlu 5 (26) . Each mutation abolished mGlu 5 activation by two orthosteric agonists, glutamate and DHPG ( Figure 2B ). However, robust agonist activity of VU0424465 was maintained at each of the mGlu 5 orthosteric mutations ( Figure 2B ). Mutation of A809V results in a loss of function of ligands that act at the mGlu 5 MPEP allosteric binding site (27) , whereas potentiation by the non-MPEP site PAM, N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybe nzamide (CPPHA), is lost with the F585I mutation (28) . Therefore, agonism by glutamate and DHPG, as well as VU0424465, was evaluated at these mGlu 5 allosteric site mutations. Glutamate and DHPG agonist activity was maintained in cells expressing mGlu 5 -F585I and mGlu 5 -A809V. Likewise, VU0424465 induced significant activation at mGlu 5 -F585I ( Figure 2C ). However, VU0424465-induced agonist activity was completely abolished in cells expressing mGlu 5 -A809V ( Figure 2C ). Altogether, these data strongly support the hypothesis that VU0424465 acts as an allosteric agonist that binds to the allosteric MPEP site.
VU0424465-Induced Agonist Activity in Native Systems
Previous reports suggest that allosteric agonist activity of mGlu 5 PAMs in cell-based systems may be an artifact of artificially high receptor expression levels (9) . VU0424465 is the first mGlu 5 -selective agonist not based on the glutamate structure that has agonist activity in cell lines expressing low levels of mGlu 5 . To determine whether VU0424465 possesses agonist activity in native systems, we assessed its ability to evoke calcium mobilization responses in rat cortical astrocytes and established electrophysiologic responses to mGlu 5 activation in rat brain slices. In contrast to previously characterized Figure 4 . The metabotropic glutamate receptor subtype 5 (mGlu 5 ) agonist positive allosteric modulator (PAM) VU0424465, but not the pure PAM VU0361747, induces epileptiform activity in CA3 in the hippocampal formation. Interevent interval (IEI) and amplitude of spontaneous firing were measured using field recordings in CA3 of the hippocampal formation. (A) Application of 50 mmol/L dihydroxyphenylglycine (DHPG) or 10 mmol/L VU0424465 for 10 min induced a robust decrease in the interevent interval of spontaneous firing while having no significant effect on the amplitude (n ¼ 8). In contrast, application of 10 mmol/L VU0361747 had no effect on either the interevent interval or amplitude of spontaneous firing (n ¼ 8). In the presence of 10 mmol/L 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine (MTEP), 10 mmol/L VU0424465 had no effect on the interevent interval or amplitude of spontaneous firing (n ¼ 7). Error bars represent SEM. (B) Sample traces taken predrug (control) and after administration of compound. (C) Cumulative probability plots for the compounds of interest.
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A well-characterized response to mGlu 5 activation in the CNS is mGlu 5 agonist-induced LTD of transmission at the Schaffer collateral-CA1 synapse in the hippocampus. Orthosteric agonists, such as DHPG (group I mGlu agonist), evoke a prolonged LTD response. In contrast, previously evaluated mGlu 5 PAMs do not induce LTD alone but potentiate the response to DHPG (5, 9) . Unlike previous PAMs, treatment with VU0424465 (10 mmol/L) alone induced a pronounced LTD response, with depression of the field excitatory postsynaptic potential (fEPSP; 38.3 Ϯ 8.7% of baseline) that persisted for at least 55 min after compound washout ( Figure 3A ). DHPG and VU0424465 induced maximum depressions of synaptic responses to -.7% Ϯ 1.3% and 38.0% Ϯ 3.4% of baseline fEPSPs, respectively. Thus, VU00424465 exhibits strong agonist activity in hippocampal slices ( Figure 3B ). In contrast, addition of the pure mGlu 5 PAM VU0361747 (9) alone had no effect on fEPSP slope (103.0% Ϯ 2.0% of baseline; Figure 3B ), consistent with our previous report (9) .
VU0424465-Induced Epileptiform Activity in Area CA3 in the Rat Hippocampus
The agonist activity of VU0424465 observed in astrocytes and induction of hippocampal LTD is the first demonstration that a compound classified as an agonist-PAM in in vitro assays has agonist activity in native CNS preparations. For PAMs targeting mGlu 5 , this may be especially important because orthosteric agonists of group I mGlus, such as DHPG, can induce epileptiform seizure activity in hippocampal slices (29) (30) (31) . Thus, we performed studies to determine whether VU0424465 can induce epileptiform activity in CA3 pyramidal neurons in hippocampal slices in a manner similar to that seen with nonselective group I mGlu receptor agonists. In parallel, VU0361747, a pure mGlu 5 PAM with no agonist activity in any recombinant or native system was evaluated (9) . Consistent with previous reports, application of 50 mmol/L DHPG induced robust epileptiform activity, as evidenced by the decreased interevent interval of spontaneous field population spikes observed using field potential recordings in the pyramidal cell body layer of area CA3 in hippocampal slices (42.9% Ϯ 4.6% of baseline interevent interval). DHPG had no significant effect on the amplitude of population spikes (125.6% Ϯ 17.2% of baseline). Interestingly, application of VU0424465 (10 mmol/L) also induced robust epileptiform activity with a decrease in the interevent interval (51.7% Ϯ 7.8% of baseline) and no effect on amplitude (105.9% Ϯ 3.7% of baseline) of spontaneous population spikes similar to that observed with DHPG. In contrast, treatment of slices with 10 mmol/L of the pure PAM VU0361747 had no significant effect on either the interevent interval (86.5% Ϯ 11.7% of baseline) or amplitude (99.4% Ϯ 3.9% of baseline) of spontaneous firing (Figure 4) .
To confirm VU0424465 effects were mediated by mGlu 5 , we determined the effect of the mGlu 5 allosteric antagonist MTEP on the response to VU0424465. Slices were treated with MTEP (10 mmol/L) for 10 min before the coaddition of 10 mmol/L MTEP and 10 mmol/L VU0424465 for an additional 10 min. In the presence of MTEP, VU0424465 had no significant effect on the interevent interval (98.8% Ϯ 11.8% of baseline) or amplitude (106.8% Ϯ 10.8% of baseline) of spontaneous population spikes in area CA3 (Figure 4) . When MTEP was added alone, a slight increase in the interevent interval was observed (143.0% Ϯ 14.4% baseline), with no effect on amplitude (100.1% Ϯ 5.4% of baseline) of spontaneous firing. Collectively, these results suggest that VU0424465 induces epileptiform activity in CA3 pyramidal neurons and this activity is dependent on agonism of mGlu 5 .
Seizure Activity and Behavioral Convulsions in Rats Following Administration of VU0424465
In addition to their ability to induce epileptiform activity in hippocampal slices, previous studies reveal that intracerebroventricular injection of Group I mGlu agonists such as DHPG can induce behavioral convulsions in rats (15, 16) . Given that VU0424465 has mGlu 5 agonist activity and induces epileptiform activity in slices, we assessed the ability of VU0424465 to induce behavioral convulsions in rats. Male Sprague-Dawley rats (275-300 g) were administered VU0424465 (.1-10 mg/kg, intraperitoneal [IP], 10% Tween 80), and behavioral responses were monitored continuously for 2 hours. Behavioral convulsions were measured using a modified Racine score (0-5). Systemic administration of VU0424465 induced a dose-dependent increase in observed behavioral manifestations of seizure activity with peak responses observed approximately 1 hour after injection ( Figure 5) . A dose-response analysis revealed that measurable responses (stage 1 on Racine scale) could be observed with doses as low as .1 mg/kg (IP) and that 3 mg/kg VU0424465 was capable of inducing fully generalized stage 5 behavioral convulsions ( Figure 5 ). In contrast, administration of a much higher dose of the pure PAM VU0361747 (56.6 mg/kg, IP) induced no measureable behavioral disturbances at any time point ( Figure 5 ). The mGlu 5 allosteric antagonist, MTEP (3 or 10 mg/kg, IP) induced a dose-dependent blockade of the behavioral response to VU0424465 (10 mg/kg) with complete blockade of VU0424465-induced behavioral convulsions at 10 mg/kg MTEP ( Figure S3 in Supplement 1). These data are consistent with the in vitro data and suggest that the behavioral effects are mediated by activation of mGlu 5 . Consistent with these behavioral manifestations, continuous video-electroencephalographic monitoring from a cortical surface electrode revealed that 10 mg/kg VU024465 induced intense behavioral and generalized electrographic seizure activity developing into electrographic status epilepticus ( Figure 6B ). In contrast, 56.6 mg/kg VU361747 did not induce any measureable behavioral or electrographic response ( Figure 6C ). These data do not rule out the possibility that VU0361747 induces focal seizure activity in another brain region not detected by the cortical electrode. However, they provide clear evidence that this pure PAM does not induce generalized seizure activity that manifest as behavioral convulsions.
To assess the brain exposure of VU0424465 and VU0361747 after systemic administration, brains were obtained 2 hours after animals received 10 mg/kg VU0424465 and 56.6 mg/kg VU0361747 and analyzed for unbound drug concentrations. The free fraction of VU0424465, as determined by brain homogenate binding, is .007. A 10-mg/kg dose of VU0424465, which induces seizure activity in vivo and maximal behavioral convulsions, corresponded to an unbound brain concentration of VU0424465 of 22.0 Ϯ 1.5 nmol/L ( Figure S4 in Supplement 1). Interestingly, the unbound brain concentration of VU0361747 achieved following administration was more than 50 times higher (1107.2 Ϯ 34.1 nmol/ L; Figure S3 in Supplement 1) than those following administration of VU0424465 with the fraction unbound in the brain being .0956 as previously reported (9) . Thus, the pure mGlu 5 PAM did not induce observable seizure activity or behavioral convulsions despite achieving high brain concentrations well above those required for maximal potentiation of mGlu 5 responses and that are 50 times higher than those of VU0424465 that induce maximal fully generalized seizure activity.
Discussion
Positive allosteric modulation of mGlus has emerged as an exciting new therapeutic strategy for major brain disorders, including schizophrenia, cognitive impairments, and some genetic childhood developmental disorders, and they are being rapidly advanced in drug development efforts (1) (2) (3) (4) . It has been postulated that targeting allosteric sites to avoid direct activation of the receptor could lower the risk of adverse effects that may occur than with agonist-induced overstimulation. This may be especially important for mGlu 5 activators because previous studies suggest that agonists of group I mGlus induce seizure activity resulting in excitotoxicity and neuronal damage (15, 32) . Previous antagonist studies suggest that mGlu 5 activation participates in the induction of seizure activity (16) . Additionally, multiple genetic developmental disorders involving epilepsy implicate disruptions in mGlu 5 signaling as a possible cause of pathogenesis (2) . Therefore, seizure activity is an adverse effect that might be expected for a traditional mGlu 5 agonist but hoped to be avoided with allosteric modulation. Using pharmacologic and mutagenesis techniques, these studies demonstrate that some mGlu 5 PAMs can act as functional agonists via an allosteric binding site on mGlu 5 . This agonist activity is observed in cell lines with low mGlu 5 expression levels similar to receptor densities observed in native preparations, as well as in multiple native systems, suggesting the agonist activity is not an artifact of mGlu 5 over expression in cell-based systems. Furthermore, differences in the in vitro profile of different mGlu 5 PAMs can translate into fundamentally different in vivo effects, with mGlu 5 allosteric agonists inducing intense seizure activity and behavioral convulsions. This provides the first direct evidence that pure allosteric potentiators that do not possess agonist activity in either in vitro systems or in vivo can avoid severe adverse effects observed with agonists. These results suggest that the presence or absence of allosteric agonist activity in a given mGlu 5 PAM series could be a major differentiating factor for novel mGlu 5 PAMs in terms of adverse effect liability.
Another key finding is that minor alterations to the chemical structure of pure mGlu 5 PAMs results in a "molecular switch," changing the in vitro profile of the compound from pure potentiation of orthosteric agonist activation to robust allosteric agonist activity. Such molecular switches in the in vitro efficacy profile of a series of mGlu 5 PAMs can introduce major complications in drug discovery efforts to optimize novel efficacious compounds with the absence of adverse effect liability. These results illustrate the need to use cell lines that express relatively low mGlu 5 levels to allow unambiguous identification of allosteric agonists versus pure PAMs in discovery efforts. Although preliminary studies suggest that VU0422465 is highly metabolically stable and does not appear to generate active metabolites, it is conceivable that structural changes through hepatic metabolism could yield metabolites that have different pharmacologic effects from the parent compound. In addition to molecular switches from PAM to allosteric agonist shown here, we have previously reported closely related compounds can display PAM versus negative allosteric modulator activity (33) . Thus, it is important to monitor and evaluate carefully the activities of major metabolites of parent mGlu 5 PAMs to ensure the parent compound is responsible for primary in vivo effects observed. Finally, an important consideration is that some patient populations may be especially sensitive to mGlu 5 PAMs. For instance, mGlu 5 PAMs have been raised as a possible approach to treatment of tuberous sclerosis (2), a genetic childhood developmental disorder. One prominent symptom of tuberous sclerosis is epileptic seizure activity. Although the present results provide a possible path that may avoid exacerbation of seizure activity in treating these patients, it is conceivable that pure PAMs will have effects in patient populations that have underlying epileptic disorders that are not observed in the majority of patients. Thus, it will be critical to evaluate carefully the multiple properties of mGlu 5 PAMs, including metabolites and possible adverse effect liability in specific patient populations.
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